Trials
3 active
5 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube”In the company’s words, NCT06719141 on ClinicalTrials.gov
- Tested for
- Developmental and Epileptic Encephalopathy (2 trials), Dravet Syndrome
- Main trialPhase 3
- “This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.”In the company’s words, NCT06719141 on ClinicalTrials.gov
- Other names
- Bexicaserin
Other drugs for Developmental and Epileptic Encephalopathy
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- EverolimusNovartis Pharmaceuticals · Phase 3
- CarisbamateSK Life Science, Inc. · Phase 3
- Clemizole HClEpygenix · Phase 3
- ZX008Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. · Phase 3
Coming up2
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
- 11 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Oct 2026 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) | |
| Phase 3Active, not recruiting | 31 Dec 2026 | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | |
| Phase 3Enrolling by invitation | 11 Nov 2027 | A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | |
| Phase 2Completed | 20 Dec 2024 | Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy | |
| Phase 1/2Completed | 16 Nov 2023 | Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026